PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16518417-5	2006	In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner.	Dicumarol	79-89	H3 histone pseudogene 16	Homo sapiens	118-121	
19583730-8	2010	The combined treatment with dicoumarol suppressed p53/p21 induction by doxorubicin and resulted in sequential p38 MAPK activation, myeloid cell leukaemia 1 suppression and caspase cleavage.	Dicumarol	28-38	H3 histone pseudogene 16	Homo sapiens	54-57	
19583730-10	2010	CONCLUSION: These results suggest that concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways.	Dicumarol	58-68	H3 histone pseudogene 16	Homo sapiens	170-173	
16518417-7	2006	These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Dicumarol	29-39	H3 histone pseudogene 16	Homo sapiens	137-140